Investigational Protocol
Retatrutide Dosing Timeline: Phase 3 Protocol
The Phase 3 TRIUMPH trial protocol uses a 5-step dose escalation starting at 1 mg and reaching 12 mg weekly. This page describes that investigational protocol for educational purposes only.
⚠ Investigational drug — not FDA-approved
Retatrutide is currently in Phase 3 clinical trials. It is not available by prescription and not approved for human use outside of clinical trials. This page is educational only.
🚫 Not for Self-Administration
The dosing schedule below describes the investigational clinical trial protocol. This information is NOT a prescribing guide and should NOT be used to self-administer any substance. Retatrutide cannot be legally obtained outside of registered clinical trials.
⚠ TRIUMPH-4 Safety Signal: Dysesthesia (December 2025)
The December 2025 TRIUMPH-4 Phase 3 readout identified dysesthesia (abnormal skin sensation — tingling, crawling, or prickling) as a new safety signal not previously observed in Phase 2:
- 9 mg arm: 8.8% dysesthesia rate (vs 0.7% placebo)
- 12 mg arm: 20.9% dysesthesia rate (vs 0.7% placebo)
- Discontinuation rates: 12.2% (9 mg) and 18.2% (12 mg) vs 4% placebo
- Lilly stated dysesthesia did not appear to drive discontinuation
Source: BioSpace, December 2025. Full characterization pending peer-reviewed publication. This signal underscores the importance of clinical trial oversight for investigational compounds.
Phase 3 Dose Escalation Schedule
Based on the published Phase 2 trial design and the TRIUMPH Phase 3 trial protocols registered on ClinicalTrials.gov, the dose escalation schedule for retatrutide in Phase 3 follows a stepwise 4-week titration:
1 mg/week — Starting Dose
Initiates GIP, GLP-1, and glucagon receptor engagement at a low level to minimize early GI side effects. Receptor adaptation begins. Most patients tolerate this dose well.
⚠ Investigational protocol — not for clinical use
2 mg/week — First Escalation
Increased receptor engagement. Appetite suppression effects become more pronounced. Nausea incidence may increase temporarily during this transition. Weight loss typically begins to accelerate.
⚠ Investigational protocol — not for clinical use
4 mg/week — Midpoint Escalation
Significant increase in dose with concurrent increase in glucagon receptor activity. Energy expenditure begins to increase measurably. Phase 2 data suggests strong weight loss response at 4 mg for some patients.
⚠ Investigational protocol — not for clinical use
8 mg/week — High-Dose Escalation
Phase 2 data showed that the 8 mg dose produced ~16% weight loss at 24 weeks — already exceeding semaglutide's maximum efficacy. GI side effect rates begin to stabilize as receptor adaptation progresses.
⚠ Investigational protocol — not for clinical use
12 mg/week — Maximum Protocol Dose
The 12 mg dose is the maximum studied in Phase 2 and Phase 3. Phase 2 data: 24.2% mean weight loss at 48 weeks. TRIUMPH-4 Phase 3 data: 28.7% mean weight loss. Full metabolic benefits are observed at this dose level.
⚠ Investigational protocol — not for clinical use
Comparison to Approved GLP-1 Titration Schedules
| Drug | Starting Dose | Max Dose | Steps | Total Titration |
|---|---|---|---|---|
| Retatrutide ⚠ | 1 mg | 12 mg | 5 steps | ~24 weeks to max dose |
| Tirzepatide | 2.5 mg | 15 mg | 6 steps | ~20 weeks to max dose |
| Semaglutide 2.4 mg | 0.25 mg | 2.4 mg | 5 steps | ~16 weeks to max dose |
| Liraglutide 3 mg | 0.6 mg/day | 3.0 mg/day | 5 steps | ~16 weeks to max dose |
⚠ Retatrutide data is from investigational clinical trial protocol. All other data is from FDA-approved prescribing information.
Why the Slow Titration?
The gradual dose escalation (1 → 2 → 4 → 8 → 12 mg) is designed to:
- Minimize early GI side effects (nausea, vomiting, diarrhea) that are characteristic of GLP-1/GIP receptor agonism
- Allow receptor adaptation — the chemoreceptor trigger zone and gut gradually adapt to higher levels of receptor activation
- Reduce the risk of adverse cardiovascular events (heart rate increases, which can occur with glucagon receptor activation at higher doses)
- Optimize tolerability to maximize the number of patients who reach the therapeutic maximum dose
Lipase Elevation: A Key Safety Signal
Phase 2 data for retatrutide noted dose-dependent increases in serum lipase levels. Elevated lipase is a potential marker of pancreatic stress and was observed in a higher proportion of patients at 8 mg and 12 mg doses compared to lower doses. This safety signal is being monitored closely in Phase 3 TRIUMPH trials. Patients with personal or family history of pancreatitis are typically excluded from trials.
For Patients Interested in Clinical Trials
If you are interested in potentially accessing retatrutide through the TRIUMPH trial program, speak with your physician about eligibility. ClinicalTrials.gov listings for the TRIUMPH program include trials for patients with obesity, type 2 diabetes, cardiovascular disease, and obstructive sleep apnea. See our TRIUMPH Trial Tracker for NCT IDs and enrollment status.
Compare to Approved Medications
Frequently Asked Questions
What dosing schedule did Phase 2 retatrutide use?
Phase 2 used weekly subcutaneous injection with 4-week titration steps starting at 2 mg, escalating to maintenance doses of 4 mg, 8 mg, or 12 mg depending on the study arm. The highest weight loss occurred in the 12 mg arm.
Is the Phase 3 dosing the same as Phase 2?
The TRIUMPH program uses similar titration with weekly subcutaneous administration. Specific dose arms have not been fully disclosed but include the 12 mg target dose from Phase 2.
Why are GLP-1 titrations always 4 weeks per step?
Four weeks is approximately the receptor desensitization adaptation timescale. Faster titrations produce more side effects without faster weight loss; slower titrations delay achieving the target dose where most weight loss occurs.
Can patients skip titration steps if tolerating well?
Standard protocols do not skip steps. The 4-week interval is for body adaptation regardless of subjective tolerability. Skipping steps increases side effect risk significantly without faster outcome benefit.
When would dose reduction be appropriate?
Persistent severe nausea or vomiting beyond the typical 1–2 week adaptation period at a new dose level is a reason to step down. Decisions are made with the prescribing physician based on the specific clinical situation.